- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07585591
Safety and Efficacy Evaluation of the Xerf Device for Aesthetic Treatments
Safety and Efficacy Evaluation of the XERF Device for Aesthetic Treatments
The goal of this clinical study is to evaluate the safety and clinical effectiveness of the XERF noninvasive dual-frequency monopolar radiofrequency device for aesthetic improvement of facial aging, including fine lines and wrinkles, eyebrow lifting, and tightening of lax tissue in the lower face, submental area, and neck in healthy adults.
Up to 60 participants may be enrolled across up to five clinical sites in the United States. Participants receive XERF treatments using 6.78 MHz and 2.0 MHz energy; most undergo two sessions approximately four weeks apart (the protocol allows up to three). Standardized photographs are taken at baseline and follow-up visits.
Outcomes are assessed approximately 30 and 90 days after the final treatment. Effectiveness is evaluated using investigator-assessed global aesthetic improvement and participant-reported satisfaction, while safety and tolerability are assessed through procedural pain ratings and monitoring of adverse events throughout the study.
Visão geral do estudo
Status
Intervenção / Tratamento
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Illinois
-
Naperville, Illinois, Estados Unidos, 60563
- Oak Dermatology
-
-
Maryland
-
Hunt Valley, Maryland, Estados Unidos, 21030
- Maryland Dermatology Laser, Skin, & Vein Institute, LLC
-
-
New Jersey
-
Montclair, New Jersey, Estados Unidos, 07042
- New Jersey Plastic Surgery
-
-
Pennsylvania
-
Devon, Pennsylvania, Estados Unidos, 19333
- Laser & Skin Surgery Center of Pennsylvania
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- 22 - 70 years old
- Is willing to undergo study device use.
- Has not received any toxin/filler in the treatment area in the past 6 months and agrees to not receive any throughout the study.
- Willing to maintain current diet and exercise routine throughout study duration.
- Understands and accepts the study condition to not receive any other procedures to the treatment area or to undergo any procedures, take any medications, supplements, or partake in any treatments indicated for weight loss or body contouring throughout the length of the study.
- Understands and accepts the study condition of and agrees that he or she is able to be present for all study visits.
- Willing to comply with all requirements of the study and is able to provide written informed consent.
Exclusion Criteria:
- Is female and pregnant, has been pregnant within the last 3 months, is currently breast feeding, or planning a pregnancy during the study period.
- Has an implanted pacemaker, internal ventricular fibrillation controller (AICD), or any electrical device.
- Has a metal implant that interferes with the transmission of energy to the electrical field.
- Has received permanent fillers or facial implants.
- Has a detected pathological abnormality.
- Has a medical condition with potentially decreased function of the peripheral nervous tissue, such as but not limited to diabetes or multiple sclerosis.
- Has an infection or infected tissue in the treatment area.
- Unable or not willing to follow instructions for pre- and post-treatment care
- Recent history of smoking (1 month)
- Has unrealistic treatment expectations.
- Has a history of herpes simplex in which the patient is not willing/able to receive preventive antiviral therapy.
- Has a blood disorder and taking aspirin or blood disorder medications.
- Has a malignant disease, cancer, or uncontrolled autoimmune disease.
- Had previous surgical or cosmetic procedures in the treatment area in the last 3 months that could interfere with the treatment procedure (including but not limited to dermabrasion, chemical peels, laser skin resurfacing, fat augmentations, topical retinoids and radiofrequency treatments)
- Currently enrolled in an investigational drug or device trial, or has received an investigational drug or been treated with an investigational device within the area to be treated 6 months prior to entering this study
- Has any condition or is in a situation which, in the investigator's opinion, may put the subject at significant risk, may confound study results, or may interfere significantly with the subject's participation.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: XERF Treatment
|
Participants received treatment with a noninvasive contact monopolar radiofrequency (RF) device (XERF) operating at 6.78 MHz and 2.0 MHz.
The device delivers RF energy using depth-dependent settings (Shallow, Middle, and Deep) selected based on the target condition and facial anatomic zone.
Treatments were performed with the EFFECTOR 60 tip using sliding mode, stamping mode, or a combination, after facial cleansing and application of a thin film of ultrasound gel.
Adjustable cryogen gas cooling (ICD Levels 1-3) was used for epidermal protection and comfort; no topical anesthesia was used.
Participants underwent two treatment sessions approximately 4 weeks apart (the protocol allowed up to three sessions).
The number of shots and total energy delivered (joules) were recorded for each treatment area.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Clinician-Scored Global Aesthetic Improvement Scale (GAIS) Responder Rate
Prazo: 90 days after the final treatment
|
Proportion of participants with a GAIS score ≥3 (on a 5-point scale, 1-5), assessed by site principal investigators using standardized clinical photographs.
A GAIS score ≥3 was considered an effective clinical improvement.
|
90 days after the final treatment
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Patient Satisfaction Score (PSS) Responder Rate
Prazo: 30 and 90 days after the final treatment
|
Proportion of participants with a Patient Satisfaction Score (PSS) ≥4 on a 6-point scale (1 = extreme dissatisfaction; 6 = significant satisfaction), assessed at follow-up visits.
|
30 and 90 days after the final treatment
|
|
Clinician-Scored Global Aesthetic Improvement Scale (GAIS) Responder Rate at 30 Days
Prazo: 30 days after the final treatment
|
Proportion of participants with a GAIS score ≥3 on a 5-point scale (1-5), assessed by site principal investigators using standardized clinical photographs.
GAIS ≥3 was considered effective improvement.
|
30 days after the final treatment
|
|
Incidence of Adverse Events
Prazo: From first treatment through 90 days after the final treatment
|
Number and proportion of participants experiencing treatment-emergent adverse events, documented throughout the study and follow-up.
|
From first treatment through 90 days after the final treatment
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Outros números de identificação do estudo
- LMP24001
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Flacidez da Pele Facial
-
Pontificia Universidad Catolica de ChileHospital del Trabajador de Santiago; SymbiOx Inc.RecrutamentoSkin de pensamento total da crônica ferida | Skin de espessura total agudaChile
-
Utah State UniversityAtivo, não recrutandoDistúrbio de Escoriação (Skin-Picking)Estados Unidos
-
Solventum US LLC3MRescindidoAplicação de pós-produto de redução bacteriana da Skin FloraEstados Unidos
-
Karolinska InstitutetRegion StockholmConcluídoTricotilomania | Distúrbio de Escoriação (Skin-Picking)Suécia
-
Northwestern UniversityConcluídoDor Facial Atípica | Dor Facial TípicaEstados Unidos
-
Kirsten JohnsonRecrutamentoCarcinoma de células escamosas da pele | Carcinoma Basocelular da Pele | CARCINOMA BASAL NODULAR DO SKINEstados Unidos
-
University of PittsburghConcluídoTextura da pele facial | Pigmentação da pele facialEstados Unidos
-
University of UtahConcluídoSincinese | Assimetria facial | Lesões do Nervo Facial | Paresia Facial Associada à Disfunção do Nervo Facial
-
Hôpital NOVOAtivo, não recrutandoAssimetria facial | Procedimentos cirúrgicos reconstrutivos | Morfologia facialFrança
-
Misr University for Science and TechnologyRecrutamento